Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Androgen deprivation therapy for prostate cancer and risk of dementia.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J.

BJU Int. 2019 Jan 13. doi: 10.1111/bju.14666. [Epub ahead of print]

PMID:
30637900
2.

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.

3.

Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.

O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M.

BJU Int. 2016 Sep;118(3):391-8. doi: 10.1111/bju.13360. Epub 2015 Nov 19.

4.

Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.

Chung SD, Lin HC, Tsai MC, Kao LT, Huang CY, Chen KC.

Andrology. 2016 May;4(3):481-5. doi: 10.1111/andr.12187. Epub 2016 Apr 7.

5.

Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S.

JAMA. 2013 Jul 17;310(3):289-96. doi: 10.1001/jama.2013.8638.

PMID:
23860987
6.

Association Between Androgen Deprivation Therapy and Risk of Dementia.

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH.

JAMA Oncol. 2017 Jan 1;3(1):49-55. doi: 10.1001/jamaoncol.2016.3662.

PMID:
27737437
7.

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

Eur Urol. 2019 Apr;75(4):676-683. doi: 10.1016/j.eururo.2018.11.022. Epub 2018 Nov 26.

PMID:
30497883
8.

Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.

Nguyen C, Lairson DR, Swartz MD, Du XL.

Pharmacotherapy. 2018 Oct;38(10):999-1009. doi: 10.1002/phar.2168. Epub 2018 Sep 4.

PMID:
30080934
9.

Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.

Eur Urol. 2017 Dec;72(6):920-928. doi: 10.1016/j.eururo.2017.06.036. Epub 2017 Jul 12.

10.

Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.

Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L.

J Clin Oncol. 2017 Jan 10;35(2):201-207. Epub 2016 Nov 21.

PMID:
27870566
11.

Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.

Baik SH, Kury FSP, McDonald CJ.

J Clin Oncol. 2017 Oct 20;35(30):3401-3409. doi: 10.1200/JCO.2017.72.6109. Epub 2017 Aug 25.

12.

Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.

Young JWS, Sutradhar R, Rangrej J, Marras C, Fleshner N, Alibhai SMH.

World J Urol. 2017 Sep;35(9):1417-1423. doi: 10.1007/s00345-017-2010-z. Epub 2017 Feb 15.

PMID:
28204918
13.

Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

Eur Urol. 2014 Mar;65(3):620-7. doi: 10.1016/j.eururo.2012.11.052. Epub 2012 Dec 6.

14.

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.

J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792. Epub 2015 Mar 2.

PMID:
25732167
15.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026. Epub 2014 Jan 28.

PMID:
24495466
16.

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.

Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L.

Eur Urol. 2016 Jul;70(1):56-61. doi: 10.1016/j.eururo.2015.06.022. Epub 2015 Jun 29.

PMID:
26138040
17.

Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.

Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E, Oger E.

Eur J Cancer. 2017 May;77:99-108. doi: 10.1016/j.ejca.2017.03.002. Epub 2017 Apr 5.

PMID:
28390298
18.

Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.

Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV.

Cancer. 2015 Aug 15;121(16):2713-9. doi: 10.1002/cncr.29420. Epub 2015 Apr 29.

19.

Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.

Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.

BJU Int. 2016 Aug;118(2):221-9. doi: 10.1111/bju.13203. Epub 2015 Jul 22.

20.

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.

Chiang IN, Huang CY, Pu YS, Chang CH, Muo CH, Chung CJ, Wang RY, Young TH.

BMJ Open. 2017 Feb 28;7(2):e012950. doi: 10.1136/bmjopen-2016-012950.

Supplemental Content

Support Center